Pleased to have participated in the oversubscribed $17.2M seed financing of Tolerance Bio, a Philadelphia based #biopharma pioneering thymus-based therapies for immune-mediated diseases.
News here: https://t.co/aNHjz2kt8N
#portfolionews#venturecapital#biotech#immunology
Pleased to have participated in the oversubscribed $17.2M seed financing of Tolerance Bio, a Philadelphia based #biopharma pioneering thymus-based therapies for immune-mediated diseases.
News here: https://t.co/aNHjz2kt8N
#portfolionews#venturecapital#biotech#immunology
@sanofi@Amgen Tolerance Bio is developing an allogeneic, or “off the shelf”, thymus iPSC-based #celltherapy platform along w pharmacological thymus therapies to address immune-mediated diseases caused by abnormalities in immune tolerance like autoimmune diseases, transplant rejection & cancer
📢Pablo Cironi (@CriteriaBioVC) resume los highlights de su intervención y el papel de Caixa Capital Risk
📍Taller 'Introducción a la Innovación y Transferencia en Biomedicina y Salud' de ASEICA-@FundlaCaixa@msmelanoma
ℹ️:https://t.co/ZGRiLRYpAn
Next week we will be attending #BioEquityEurope 2024 in San Sebastian to meet #biotech entrepreneurs and catch up with #pharma industry leaders and fellow #venturecapital investors.
If you are also participating, get in touch with us to arrange a meet up! 🤝
🔛🟢 The second edition of the #ConnectionDay24 is on!
Many thanks to all attendees for your trust and for having exceeded expectations, once again, this year. Let networking and connections begin!
#WeAreCataloniaBioHT
Next week we will be attending #BIOEuropeSpring 2024 in Barcelona to meet #biotech entrepreneurs and catch up with #pharma industry leaders and fellow #venturecapital investors.
If you are also participating, get in touch with us to arrange a meet up! 🤝
Thrilled to announce the well-deserved promotions of @RubenSebas_ and Salvatore Cappadona to Senior Associates within our investment team 🚀
Their exceptional talent and invaluable contributions have been instrumental in driving our mission forward. Congrats Ruben & Salvatore!
Today Pablo Cironi, Managing Director, and @RubenSebas_, Sr Associate, are representing @CriteriaBioVC at CNIO Investor's Day 2024.
A great event to interact with the scientists of one of the leading cancer research centers worldwide.
@CNIOStopCancer#cancertherapy#innovation
We are launching new @X profiles! From today we will share our #VC activity on #Tech topics from the account @CriteriaVT. Everything related to #Biotech and #LifeSciences will be available at @CriteriaBioVC.
Follow us ⬇️!
🔬https://t.co/QpPaqykoGT
🤖https://t.co/WbmbjgN72i
Exciting news! Our new website is live, providing a fresh look into Criteria Bio Ventures. Follow us for updates on our portfolio, team activities, and more.
Let the journey begin! 🚀
#CBVnews#venturecapital#biotech#lifesciences#pharma
https://t.co/MV7pBNuP7p